RU2558534C2 - Способы предупреждения или лечения саркопении и мышечной атрофии у животных - Google Patents

Способы предупреждения или лечения саркопении и мышечной атрофии у животных Download PDF

Info

Publication number
RU2558534C2
RU2558534C2 RU2012118686/13A RU2012118686A RU2558534C2 RU 2558534 C2 RU2558534 C2 RU 2558534C2 RU 2012118686/13 A RU2012118686/13 A RU 2012118686/13A RU 2012118686 A RU2012118686 A RU 2012118686A RU 2558534 C2 RU2558534 C2 RU 2558534C2
Authority
RU
Russia
Prior art keywords
isoflavones
animal
sarcopenia
animals
muscle atrophy
Prior art date
Application number
RU2012118686/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2012118686A (ru
Inventor
Юаньлун ПАН
Сунил КОЧХАР
Серж Андре Доминик РЕЦЦИ
Франсуаз-Пьер МАРТЕН
Эмма ПЁРТРЕПА
Себастьяно КОЛЛИНО
ВЕРА Франсиа АРКЕ
Original Assignee
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нестек С.А. filed Critical Нестек С.А.
Publication of RU2012118686A publication Critical patent/RU2012118686A/ru
Application granted granted Critical
Publication of RU2558534C2 publication Critical patent/RU2558534C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
RU2012118686/13A 2009-10-09 2010-10-08 Способы предупреждения или лечения саркопении и мышечной атрофии у животных RU2558534C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
US61/278,633 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (2)

Publication Number Publication Date
RU2012118686A RU2012118686A (ru) 2013-11-20
RU2558534C2 true RU2558534C2 (ru) 2015-08-10

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012118686/13A RU2558534C2 (ru) 2009-10-09 2010-10-08 Способы предупреждения или лечения саркопении и мышечной атрофии у животных

Country Status (12)

Country Link
US (1) US9301941B2 (cg-RX-API-DMAC7.html)
EP (1) EP2485740B1 (cg-RX-API-DMAC7.html)
JP (1) JP6122638B2 (cg-RX-API-DMAC7.html)
CN (1) CN102573857A (cg-RX-API-DMAC7.html)
AU (1) AU2010303872B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012008238A2 (cg-RX-API-DMAC7.html)
CA (1) CA2776950C (cg-RX-API-DMAC7.html)
ES (1) ES2688447T3 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02624A (cg-RX-API-DMAC7.html)
MX (1) MX2012004118A (cg-RX-API-DMAC7.html)
RU (1) RU2558534C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011043827A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2831143C2 (ru) * 2019-05-31 2024-12-02 Сосьете Де Продюи Нестле Са Питательная смесь на основе mct для обеспечения полезных для здоровья эффектов у животных

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
EP2717876B1 (en) * 2011-06-06 2018-12-19 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
US9913823B2 (en) * 2011-10-18 2018-03-13 Amorepacific Corporation SIRT 1 activator including syringaresinol
MY194893A (en) * 2014-04-28 2022-12-22 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside
HK1246601A1 (zh) 2015-02-13 2018-09-14 马斯公司 宠物食物饲喂系统
KR20170002846A (ko) 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
GB201721627D0 (en) 2017-12-21 2018-02-07 Mars Inc Pet food product
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
CA3156846A1 (en) * 2019-10-04 2021-04-08 Suntory Holdings Limited Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein
KR102623198B1 (ko) * 2020-02-26 2024-01-10 한국 한의학 연구원 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물
RU2756154C1 (ru) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом
KR102803173B1 (ko) * 2021-02-22 2025-05-07 한국 한의학 연구원 황기 추출물로부터 분리한 화합물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생, 근감소 또는 근피로의 예방, 개선 또는 치료용 조성물
WO2023140407A1 (ko) * 2022-01-21 2023-07-27 경상국립대학교병원 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물
KR102803976B1 (ko) * 2022-04-06 2025-05-07 국립강릉원주대학교산학협력단 때죽나무 잎 추출물을 포함하는 근력강화용 조성물
WO2025121473A1 (ko) * 2023-12-06 2025-06-12 경상국립대학교병원 아세틸제니스틴을 포함하는 근감소증의 예방 또는 개선용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1329222A1 (en) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Isoflavone compositions for use in medicine
US20050049424A1 (en) * 2001-10-25 2005-03-03 Kelly Graham Edmund 6-Hydroxy isoflavones derivatives and medicaments involving same
WO2005089567A1 (en) * 2004-03-17 2005-09-29 Nestec S.A. Compositions and methods for reducing or preventing obesity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166380B (cg-RX-API-DMAC7.html) * 1973-07-09 1975-03-28
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
IL145540A0 (en) * 2000-09-28 2002-06-30 Pfizer Prod Inc Use of growth hormone secretagogues in conjunction with physical exercise
US20070185012A1 (en) 2003-07-10 2007-08-09 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
JP2007519743A (ja) 2004-01-29 2007-07-19 エリクシアー ファーマシューティカルズ， インコーポレイテッド ウイルス障害の処置
WO2007134867A2 (en) * 2006-05-24 2007-11-29 Dsm Ip Assets B.V. Treating muscular disorders and improving muscular function
KR101202240B1 (ko) * 2006-08-24 2012-11-16 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049424A1 (en) * 2001-10-25 2005-03-03 Kelly Graham Edmund 6-Hydroxy isoflavones derivatives and medicaments involving same
EP1329222A1 (en) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Isoflavone compositions for use in medicine
WO2005089567A1 (en) * 2004-03-17 2005-09-29 Nestec S.A. Compositions and methods for reducing or preventing obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AUBERTIN-LEHEUDRE M ET AL:"Six months of isoflavone supplement increases fat-free mass in obese-sarcopenic postmenopausal women: a randomized double-blind controlled trial" EUROPEAN JOURNAL OF CLINICAL NUTRITION, NATURE PUBLISHING GROUP, GB, vol. 61, no. 12, 1 December 2007 (2007-12-01), pages 1442-1444. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2831143C2 (ru) * 2019-05-31 2024-12-02 Сосьете Де Продюи Нестле Са Питательная смесь на основе mct для обеспечения полезных для здоровья эффектов у животных

Also Published As

Publication number Publication date
AU2010303872B2 (en) 2016-06-23
RU2012118686A (ru) 2013-11-20
BR112012008238A2 (pt) 2017-06-06
JP2013507361A (ja) 2013-03-04
ES2688447T3 (es) 2018-11-02
EP2485740B1 (en) 2018-08-29
CA2776950C (en) 2023-11-21
CA2776950A1 (en) 2011-04-14
IN2012DN02624A (cg-RX-API-DMAC7.html) 2015-05-22
WO2011043827A1 (en) 2011-04-14
EP2485740A4 (en) 2013-04-03
MX2012004118A (es) 2012-05-08
JP6122638B2 (ja) 2017-04-26
CN102573857A (zh) 2012-07-11
US9301941B2 (en) 2016-04-05
AU2010303872A1 (en) 2012-04-19
EP2485740A1 (en) 2012-08-15
US20120238515A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
RU2558534C2 (ru) Способы предупреждения или лечения саркопении и мышечной атрофии у животных
JP5820819B2 (ja) カロリー制限の模倣に有効な食餌療法
US8263646B2 (en) Methods for the treatment of kidney disease
AU2009282482B2 (en) Methods for enhancing energy metabolism
AU2012243210B2 (en) Methods for regulating sirtuin gene expression
Shastak et al. A century of vitamin E: Early milestones and future directions in animal nutrition
CN101389328A (zh) 诱导骨生长和抑制骨流失的组合物和方法
Pastorelli et al. Partial replacement of synthetic vitamin E by polyphenols in post-weaning piglets
Simon et al. Nutritional Support of Chronic Obstructive Pulmonary Disease
Karembe et al. Comparison of an injectable toltrazuril–gleptoferron and an oral toltrazuril+ injectable gleptoferron in piglets: Hematinic activities and pharmacokinetics
Schedlbauer et al. Alterations of serum vitamin E and vitamin A concentrations of ponies and horses during experimentally induced obesity

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171009